Role of NADPH cytochrome P450 reductase in activation of RH1
- PMID: 17256129
- DOI: 10.1007/s00280-007-0417-8
Role of NADPH cytochrome P450 reductase in activation of RH1
Abstract
Purpose: RH1 is a new bioreductive agent that is an excellent substrate for the two-electron reducing enzyme, NAD(P)H quinone oxidoreductase 1 (NQO1). RH1 may be an effective NQO1-directed antitumor agent for treatment of cancer cells having elevated NQO1 activity. As some studies have indicated that RH1 may also be a substrate for the one-electron reducing enzyme, NADPH cytochrome P450 reductase (P450 Red), P450 Red may contribute to the activation of RH1 where NQO1 activities are low and P450 Red activities are high. The mean P450 Red activity in the human tumor cell line panel used by NCI for evaluation of new anticancer agents is 14.8 nmol min(-1) mg prot(-1), while the mean NQO1 activity in these cell lines is 199.5 nmol min(-1) mg prot(-1). Thus, we investigated whether P450 Red could play a role in activating RH1.
Methods: Reduction of RH1 by purified human P450 Red was investigated using electron paramagnetic resonance and spectroscopic assays. The ability of RH1 to produce DNA damage following reduction by P450 Red was studied using gel assays. To determine the role of P450 Red in activation of RH1 in cells, cell growth inhibition studies with inhibitors of P450 Red and NQO1 were carried out in T47D human breast cancer cells and T47D cells transfected with the human P450 Red gene (T47D-P450) that have P450 Red activities of 11.5 and 311.8 nmol min(-1) mg prot(-1), respectively.
Results: Reduction studies using purified P450 Red and NQO1 confirmed that RH1 can be reduced by both enzymes, but redox cycling was slower following reduction by NQO1. RH1 produced DNA strand breaks and crosslinks in isolated DNA after reduction by either P450 Red or NQO1. DPIC, an inhibitor of P450 Red, had no effect on cell growth inhibition by RH1 in T47D cells, and had only a small effect on cell growth inhibition by RH1 in the presence of the NQO1 inhibitor, dicoumarol, in T47D-P450 cells.
Conclusions: These results demonstrated that P450 Red does not contribute to the activation of RH1 in cells with normal P450 Red activity and plays only a minor role in activating this agent in cells with high levels of this enzyme. These studies confirmed that P450 Red could activate RH1 and provided the first direct evidence that RH1 could produce both DNA strand breaks and DNA crosslinks after reduction by P450 Red. However, the results strongly suggest that P450 Red does not play a significant role in activating RH1 in cells with normal P450 Red activity.
Similar articles
-
The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells.Free Radic Res. 2006 Sep;40(9):974-8. doi: 10.1080/10715760600833077. Free Radic Res. 2006. PMID: 17015278
-
The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.Cancer Chemother Pharmacol. 2002 Feb;49(2):101-10. doi: 10.1007/s00280-001-0395-1. Epub 2001 Nov 24. Cancer Chemother Pharmacol. 2002. PMID: 11862423
-
Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.Cancer Chemother Pharmacol. 2005 Sep;56(3):307-16. doi: 10.1007/s00280-004-0961-4. Epub 2005 May 5. Cancer Chemother Pharmacol. 2005. PMID: 15877230
-
[DT-diaphorase].Gan To Kagaku Ryoho. 1997 Sep;24(11):1606-10. Gan To Kagaku Ryoho. 1997. PMID: 9309161 Review. Japanese.
-
Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.Org Biomol Chem. 2008 Feb 21;6(4):637-56. doi: 10.1039/b715270a. Epub 2007 Dec 13. Org Biomol Chem. 2008. PMID: 18264564 Review.
Cited by
-
Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours.Br J Cancer. 2009 Jul 7;101(1):55-63. doi: 10.1038/sj.bjc.6605100. Epub 2009 Jun 2. Br J Cancer. 2009. PMID: 19491903 Free PMC article.
-
Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).Mol Pharmacol. 2008 Dec;74(6):1657-65. doi: 10.1124/mol.108.050401. Epub 2008 Sep 15. Mol Pharmacol. 2008. PMID: 18794327 Free PMC article.
-
Redox-directed cancer therapeutics: molecular mechanisms and opportunities.Antioxid Redox Signal. 2009 Dec;11(12):3013-69. doi: 10.1089/ars.2009.2541. Antioxid Redox Signal. 2009. PMID: 19496700 Free PMC article. Review.
-
Distinct activation mechanisms trigger the trypanocidal activity of DNA damaging prodrugs.Mol Microbiol. 2017 Oct;106(2):207-222. doi: 10.1111/mmi.13767. Epub 2017 Aug 31. Mol Microbiol. 2017. PMID: 28792090 Free PMC article.
-
Flavylium-Based Hypoxia-Responsive Probe for Cancer Cell Imaging.Molecules. 2021 Aug 15;26(16):4938. doi: 10.3390/molecules26164938. Molecules. 2021. PMID: 34443527 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous